FOSUN HEALTH Logo

Thyroid Cancer Diagnosis

catalogue

Thyroid Cancer Diagnosis

Thyroid Cancer Diagnosis

Diagnosis is made with an ultrasound and a needle, not an operation. Cytology classifies the nodule, staging adds the age rule, and molecular testing on the same specimen decides what happens if the disease returns.

Ultrasound: where the assessment starts

Ultrasound is the first and most informative test, and it is done before any decision about a needle. It answers four things: how big the nodule is, what it is made of, whether it has features associated with malignancy, and whether the lymph nodes beside the thyroid look normal. Neck nodes matter as much as the nodule itself, because a normal-looking primary with an abnormal node is still a nodal disease.

The features are graded rather than judged one at a time. A solid hypoechoic nodule with irregular margins, a taller-than-wide shape and microcalcification sits in the highest category; a spongiform nodule or a purely cystic one sits in the lowest. That graded score — TI-RADS — sets the size threshold for biopsy, which is why the biopsy decision is reproducible between centres rather than a matter of opinion.

Fine-needle aspiration: what it can and cannot do

A fine-needle aspiration takes cells through a thin needle, usually with ultrasound guidance. It is quick, it does not require anaesthesia, and it does not seed the tumour along the needle track — that concern is a myth, and the risk of it happening is negligible.

What it cannot do is answer a structural question. Cytology sees cells; it does not see whether a capsule has been breached. That is the reason follicular carcinoma cannot be diagnosed on a needle sample: a benign follicular adenoma and a follicular carcinoma can contain identical-looking cells, and the difference lies in whether the tumour has invaded its capsule or vessels, which requires the whole nodule. This limitation is well understood, and it is the reason a proportion of nodules go to diagnostic surgery rather than to further tests.

Reading the cytology report

Aspirates are reported in six Bethesda categories, and each carries a different probability of malignancy and a different next step:

  • Bethesda I — non-diagnostic. Not enough cells. Usually repeated, sometimes with a larger needle.
  • Bethesda II — benign. The great majority. Followed on ultrasound rather than operated on.
  • Bethesda III — atypia of undetermined significance. The largest indeterminate group, and the one where molecular testing changes management most.
  • Bethesda IV — follicular neoplasm. Cells suggest a follicular lesion; the diagnosis cannot be completed without the whole nodule, so surgery is often both diagnosis and treatment.
  • Bethesda V — suspicious for malignancy. Usually operated on.
  • Bethesda VI — malignant. Diagnostic, and surgery follows.

If your report says Bethesda III or IV, the useful question is not what the category is called but what can be done with the specimen that already exists. In many cases the answer is molecular testing, which can move the nodule into a benign or suspicious group without another needle.

Molecular testing on the same specimen

Molecular testing is performed on the aspirate that has already been taken, or on the resected tissue if surgery has happened. It has two separate uses, and they are often confused.

The diagnostic use is in indeterminate nodules. A mutation with a high probability of malignancy — BRAF V600E above all — makes a Bethesda III or IV nodule much more likely to be cancer, and a benign-expression classifier can move a nodule towards surveillance. Neither test replaces the pathologist; both sharpen a decision that would otherwise be a guess. The prognostic and therapeutic use is in disease that has already been diagnosed: BRAF, RAS, TERT and RET results feed into how complete the first operation should be, and into which targeted drug becomes available if the disease advances and stops taking up iodine.

Staging, and why age is part of it

Staging answers two questions for differentiated thyroid cancer — how far the tumour has grown beyond the gland, and whether it has reached distant organs — but the AJCC system adds a third variable that no other common cancer uses: the patient's age at diagnosis, with the dividing line at 55.

Under 55, only Stage I and Stage II exist. Stage I means any tumour with or without neck nodes and no distant spread; Stage II means distant spread is present. At or over 55, the size of the tumour, its extension into structures outside the thyroid and the involvement of nodes all count, and Stages III and IV become possible. This is why the stage should never be read without the age beside it — and why a young patient with involved nodes is often described more reassuringly than the ultrasound report alone would suggest.

Arranging the work-up from abroad

Most of a thyroid work-up can be done from your own country, and much of the value of a review is in telling you which parts are genuinely needed. What the team needs to see is not a summary but the material: the ultrasound images rather than the radiologist's paragraph, the cytology slides or block if a diagnosis is still open, and the molecular result if one has been done.

Three things commonly need to be added. A laryngoscopy documents vocal cord function before surgery, so that a pre-existing nerve weakness is not mistaken for a surgical complication afterwards. Thyroid function and antibody tests establish the baseline the hormone replacement will be built on. And a repeat ultrasound of the neck nodes by the operating team is usual practice, because nodal assessment is what decides whether a neck dissection is part of the operation.

Frequently Asked Questions

Does the biopsy spread the cancer?

No. Needle-track seeding from a thyroid fine-needle aspiration is a theoretical concern that has been looked for repeatedly and found to be negligible in practice. The needle used is very fine, it passes through the nodule rather than cutting a path through it, and the number of reported cases across decades of use is vanishingly small. The alternative — operating on a nodule without knowing whether it is malignant — carries far greater risk, which is why biopsy is the standard step rather than an optional one.

What does an indeterminate biopsy result mean?

It means the cells did not settle the question. Bethesda III and IV together account for roughly a quarter of thyroid aspirates, and the categories exist because follicular lesions cannot be classified without seeing whether the tumour capsule has been invaded. An indeterminate result is therefore not a diagnosis withheld — it is a genuine limit of what cytology can see. The two ways forward are molecular testing on the specimen already taken, or diagnostic surgery in which removing the nodule is also the way it is diagnosed.

Can I send my ultrasound and biopsy report for review before travelling?

Yes, and for thyroid cancer that review is often enough to decide the plan. What the team needs is the ultrasound images themselves rather than the text report, the cytology report with its Bethesda category, any molecular result, and the operative and pathology reports if surgery has already been performed. From those, a written assessment can state whether the nodule needs surgery at all, whether a lobectomy would be sufficient, and whether the nodal disease on imaging changes the operation. It is returned within 48 hours of the file being complete.

Why do I need a laryngoscopy before thyroid surgery?

To record how the vocal cords are moving before anything is done. The recurrent laryngeal nerve runs immediately behind the thyroid, and a tumour can already be pressing on it before any operation — sometimes without the patient noticing a voice change. If that is not documented beforehand, a pre-existing weakness is discovered after surgery and is indistinguishable from a complication of it. It takes a few minutes, it is done in clinic, and it protects both the surgical plan and the account of what happened.

Have a nodule that needs a decision?

Send your ultrasound images, cytology report with its Bethesda category, molecular results and any previous operative or pathology reports. Our thyroid team will return a written assessment within 48 hours — including whether the nodule needs an operation at all, and which operation is the right one.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*